5-HT3 receptor antagonism and psychoactivity

Journal of Psychopharmacology

Volumn 10, Issue 3, 1996, Pages 182-187

  Sullivan, John T ^a,b   Preston, Kenzie L ^a   Testa, Margaret P ^a   Bell, Joanne ^a   Jasinski, Donald R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

5 HT3 antagonism; Cocaine; Ondansetron; Psychoactivity; Subjective effects

Indexed keywords

COCAINE; ONDANSETRON; PSYCHOTROPIC AGENT; SEROTONIN 3 RECEPTOR; SEROTONIN ANTAGONIST;

ADULT; ARTICLE; CARDIOVASCULAR RESPONSE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION LOSS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ABUSE; DRUG EFFECT; HEART RATE; HUMAN; INFLUENZA; INJECTION PAIN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MENTAL DISEASE; NAUSEA; PHLEBITIS; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; VERTIGO; VISUAL IMPAIRMENT; VOMITING;

EID: 0029783020     PISSN: 02698811     EISSN: None     Source Type: Journal    
DOI: 10.1177/026988119601000302     Document Type: Article

References (25)

1. 3 receptor antagonists. An overview of their present status and future potential in cancer therapy-induced emesis. Drugs 42: 552-568
2. 3 receptor antagonist, on cognition in rodents and primates. Pharmacol Biochem Behav 35: 955-962
3. 3 receptors mediate inhibition of acetylcholine release in cortical tissue. Nature 338: 762-763
4. 3 receptor antagonist. Br J Pharmacol 90: 87
5. 3 receptor antagonists as anti-emetics. Trends Pharmacol Sci 12: 46-48
6. 3 receptor antagonists block morphine- and nicotine-induced place preference conditioning. Eur J Pharmacol 151: 159-160
7. Cochran WG, Cox GM (1957) Experimental designs, 2nd edn. John Wiley and Sons, Inc., New York
8. 3 antagonist, GR38932F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. Br J Pharmacol 92: 881-894
9. 3 receptors. Pharmacol Ther 47: 181-202
10. Fischman M, Schuster CW (1980) Cocaine effects in sleep-derived humans. Psychopharmacology 72: 1-8
11. Fozard JR, Maborok-ali ATM, Newgrosh G (1977) Selective blockade of presynaptic tryptamine receptors by (-)-cocaine and (+)-cocaine. Br J Pharmacol 61: 130-131
12. Griffith JD, Nutt JG, Jasinski DR (1975) A comparison of fenfluramine and amphetamine in man. Clin Pharmacol Ther 18: 563-670
13. Griffith JD, Jasinski DR, Casten GP, McKinney GR (1986) Investigation of the abuse liability of buspirone in alcohol-dependent patients. Am J Med 80 (Suppl 3B): 30-35
14. Jasinski DR (1977) Assessment of the abuse potentiality of morphine-like drugs (methods used in man). In Martin WR (ed.), Handbook of experimental pharmacology vol. 45/1. Drug addiction 1: morphine, sedative hypnotic and alcohol dependence. Springer-Verlag, Heidelberg, pp. 197-258
15. Jasinski DR, Henningfield JE (1989) Human abuse liability assessment by measurement of subjective and physiologic effects. In Fischman MW, Mello NK (eds), Testing for abuse liability of drugs in humans. NIDA research monograph no. 92, pp. 73-100
16. 3 receptor blockade: a preliminary study in healthy volunteers. Psychopharmacology 112: 142-144
17. Preston K L, Jasinski DR, Testa M (1991) Abuse potential and pharmacological comparison of tramadol and morphine. Drug Alcohol Depend 27: 7-17
18. Preston KL, Sullivan JT, Strain EC, Bigelow GE (1992) Effects of cocaine alone and in combination with bromocriptine in human cocaine abusera. J Pharmacol Exp Ther 262: 279-291
19. 3 receptor antagonists attenuate cocaine-induced locomotion in mice. Eur J Pharmacol 186: 327-330
20. Sullivan JT, Jasinski DR, Preston KL, Testa MP, Bell JM (1992a) Cocaine blocking effects of ondansetron. In Harris L (ed), Problems of drug dependence 1991: Proceedings of the 53rd Annual Scientific Meeting. The Committee on Problems of Drug Dependence, Inc., US Department of Health and Human Services. NIDA research monograph no. 119, p. 466
21. 1D agonist sumatriptan. Clin Pharmacol Ther 52: 635-642
22. Sullivan JT, Testa MP, Preston KL, Blum P, Jasinski DR (1994) Psychoactivity of ritanserin and its interaction with intravenous cocaine. In Harris L (ed.), Problems of drug dependence 1993: Proceedings of the 55th Annual Scientific Meeting. The College on Problems of Drug Dependence, Inc., US Department of Health and Human Services. NIDA research monograph no. 141, p. 377
23. 3 receptors suggest new treatments for psychosis and drug addiction. Trends Pharmacol Sci 10: 127-129
24. Vocci FJ (1989) The necessity and utility of abuse liability evaluations in human subjects: the FDA perspective. In Fischman MW, Mello NK (eds), Testing for abuse liability of drugs in humans. NIDA research monograph no. 92, pp. 7-20
25. Weiner N (1985) Atropine, scopolamine and related drugs. In Gilman AG, Goodman LS, Rall TW, Murod F (eds), The pharmacological basis of therapeutics, 7th edn. Macmillan Publishing Company, New York